Golden Throat Holdings Group Co Ltd
Golden Throat Holdings Group Co Ltd is a pharmaceutical company that develops, produces, and sells over-the-counter (OTC) medicines and health products, primarily in the Chinese market.
Business. Golden Throat Holdings Group Co Ltd (6896.HK) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Healthcare sector. Its business model focuses on product sales within the Pharmaceuticals & Medical Research industry group.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Golden Throat Holdings Group Co Ltd (6896.HK) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Healthcare sector. Its business model focuses on product sales within the Pharmaceuticals & Medical Research industry group.
Golden Throat Holdings Group Co Ltd has a market capitalization of 2.54 billion CNY, with a market price of 3.43 CNY per share. The company has no dilution risk, as the number of basic and diluted shares outstanding is identical at 739.3 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. Without access to key financial ratios such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's performance relative to industry benchmarks.
The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown is provided, and there is no information on the geographic distribution of its sales.
The company's growth trajectory is not quantified in the outlook data. No numeric deltas or forward-looking revenue guidance is available to assess the company's performance in the current or next fiscal year.
The company is flagged for liquidity risk due to the absence of balance-sheet inputs and no going-concern language in source documents. No dilution risk is currently present, as the number of basic and diluted shares is the same. No adjustments have been applied to the valuation metrics, and no specific dilution sources are identified in the available data.
No recent events, such as filings or transcripts, are available in the source documents to provide insight into the company's recent developments or strategic direction.
- The company has no dilution risk, as basic and diluted shares are equal.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- No profitability or return metrics are available for comparison to industry benchmarks.
- No segment or geographic revenue breakdown is disclosed in the available data.
- No forward-looking growth guidance is available to assess the company's future performance.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥992.0M, +20,9% YoY; Operating income +57,8% YoY.
- ▍Revenue ¥992.0M, +20,9% YoY
- ▍Operating income +57,8% YoY
- ▍Net income +49,9% YoY
- ▍Free cash flow +45,2% YoY
- ▍Net margin 28.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Golden Throat Holdings Group Co Ltd Market data — financials · 2026-05-27